Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Leuk Res
Main Authors:	Advani, Anjali S., Li, Hongli, Michaelis, Laura C., Medeiros, Bruno C., Liedtke, Michaela, List, Alan F., O’Dwyer, Kristen, Othus, Megan, Erba, Harry P., Appelbaum, Frederick R.
Format:	Artigo
Sprog:	Inglês
Udgivet:	2018
Fag:	Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6574123/ https://ncbi.nlm.nih.gov/pubmed/29407182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.01.021
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Lignende værker